利拉鲁肽与胰岛素泵对新诊断的2型糖尿病肥胖患者临床疗效比较

Abstract
Figure/Table
References (14)
Related Citation (5)

Download: PDF (0 KB) HTML (24 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo compare the efficacy of Liraglutide and continuous subcutaneous Insulin infusion (CSII)via pump in newly diagnosed obese patients with type 2 diabetes mellitus.MethodsFrom October 2015 to October 2016,a total of 64 patients with newly-diagnosed type 2 diabetes mellitus（DM）without application of antidiabetic drugs treated in our department were randomly divided into Liraglutide hypodermic injection group and continuous Insulin pump group.The treatment was lasted for 4 weeks.The fasting and 2-hour postprandial blood glucose,Insulin level in fasting,glycosylated hemoglobin(HbA1c),body mass index(BMI),and waist circumference were compared before and after treatment between the two groups.ResultsThe fasting plasma glucose(FPG),2-hour postprandial blood glucose(2 h PG),fasting Insulin (FINS),and HbA1c were significantly improved in the two groups compared with those before treatment,but there was no significant difference in inter-group comparisons.The BMI and waist circumference in Liraglutide group were obviously improved compared with those before treatment,and also displayed statistical differences in comparison of Insulin pump group.ConclusionFor the newly diagnosed obese patients with type 2 diabetes,the application of Liraglutide for blood glucose reduction can effectively reduce the blood glucose level,improve the function of islet β cells,and the effect is tantamount to that by Insulin pump.The former has the advantages of reducing body weight and waist circumference.

Key words： Type 2 diabetes Liraglutide Insulin pump

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Sa
	SHI Yi-shan

Cite this article:

ZHAO Sa,SHI Yi-shan. Comparison of clinical efficacy of Liraglutide and Insulin pump in newly diagnosed obese patients with type 2 diabetes mellitus[J]. 中国当代医药, 2018, 25(5): 44-46.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I5/44

[1]	Nadkarni P，Chepurny OG，Holz GG.Regulation of glucose homeostasis by GLP-1[J].Prog Mol Biol Transl Sci，2014，121：23-65
[2]	中华医学会糖尿病学分会.中国2型糖尿病防治指南2010版[M].北京：北京大学医学出版社，2011：11.
[3]	葛均波，徐永健.内科学[M].8版.北京：人民卫生出版社，2013：733-769.
[4]	佚名.IDF全球糖尿病概览（第6版）中文版公布[J].中国全科医学，2014，17（26）：3124.
[5]	GuariguataL，WhitingDR，HambletonI，etal.Globalestimatesof diabetes prevalence for 2013 and projections for 2035[J].Diabetes Res Clin Pract，2014，103（2）：137-149.
[6]	Pickup JC.Diabetes：insulin pump therapy fortype 2 diabetes mellitus[J].Nat Rev Endocrinol，2014，10（11）：647.
[7]	张耀文，欧小娟，卢燕琼，等.短期胰岛素泵强化治疗新诊断的 2型糖尿病临床观察[J].实用糖尿病杂志，2013，9（2）：33-34.
[8]	黄卫华，邱增新，曾鑫.胰岛素泵短期持续皮下注射胰岛素类似物对初诊2型糖尿病的临床疗效分析[J].中国药物经济学，2014，13（5）：63.
[9]	刘霞，张永莉.利拉鲁肽联合胰岛素泵治疗非初诊2型糖尿病的应用前景[J].中国医药导报，2014，11（23）：154-156.
[10]	卢婷婷，马向华，沈捷.利拉鲁肽的胰外作用及作用机制[J].中华临床医师杂志（电子版），2013，7（18）：8431-8434.
[11]	Mullard A.2010 FDA drug approvals[J].Nat Rev Drug Discov，2011，10（2）：82-85.
[12]	吴世斌，赵梅，温传彬，等.2型糖尿病治疗新药-利拉鲁肽[J].中国生化药物杂志，2012，33（2）：210-212.
[13]	Dharmalingam M.Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus：an Indian perspective[J].Ther Adv Endocrinol Metab，2014，5（6）：159-165.
[14]	Li Z，Ye J，He JY，et al.Effect of liraglutide in type 2 diabetes[J].J Drug Target，2014，2：517-519.